# Stan Abel

> Stan Abel is President and CEO of ProJenX, a clinical-stage biotech spun out of Columbia University research and Project ALS, racing to get its lead drug prosetin - an oral MAP4K inhibitor - into ALS patients after two decades of laboratory work and a $15 million Series A.

- **Role:** President and Chief Executive Officer at ProJenX
- **Organizations:** ProJenX, Inc., SiteOne Therapeutics, Corthera Inc., Cerexa Inc., Peninsula Pharmaceuticals Inc., Eli Lilly and Company, DowBrands Inc.
- **Nationality:** American
- **Education:** B.S. in Business, Indiana University, M.B.A., with honors, University of Chicago Booth School of Business
- **Known for:** Led or held senior finance roles at three biotech companies that were acquired by Novartis, Forest Laboratories, and Johnson & Johnson, Helped raise over $100 million across emerging life sciences companies, Closed a $15 million Series A financing for ProJenX in 2023

## Career timeline

- **early career** — Held finance positions at Eli Lilly and Company and DowBrands Inc.
- **unknown** — Served as CFO of Peninsula Pharmaceuticals Inc. through its sale to Johnson & Johnson.
- **unknown** — Served as CFO of Cerexa Inc. from inception through its sale to Forest Laboratories.
- **unknown** — Served as CEO of Corthera Inc., a heart-failure therapeutics company, through its sale to Novartis.
- **unknown** — Served as CEO and later Chairman of SiteOne Therapeutics, a pain-treatment biotech.
- **2022-04** — Joined ProJenX as President and CEO.
- **2023-11** — ProJenX announced initial closing of $15 million Series A financing led by Medical Excellence Capital; Rick Hartz appointed to the board.
- **2025** — FDA lifted a partial clinical hold on prosetin's Phase 1 trial (PRO-101), allowing dosing to proceed in ALS patients.

## Achievements

- Led or held senior finance roles at three biotech companies that were acquired by Novartis, Forest Laboratories, and Johnson & Johnson
- Helped raise over $100 million across emerging life sciences companies
- Closed a $15 million Series A financing for ProJenX in 2023
- Guided ProJenX's lead candidate prosetin through Phase 1 to an FDA orphan drug designation and past a partial clinical hold

## Latest updates

- **2023-11** — ProJenX announced the initial closing of a $15 million Series A financing round led by Medical Excellence Capital, with Rick Hartz joining the board of directors.
- **2025-01** — The FDA lifted a partial clinical hold on ProJenX's Phase 1 prosetin trial, clearing the way to dose ALS patients in the US, Canada, and Europe.

## Links

- Website: https://projenx.com
- LinkedIn: http://www.linkedin.com/in/stan-abel-9570b4b
- Twitter/X: https://twitter.com/projenx

---

Profile page: https://yespress.io/stan-abel
Published by YesPress — https://yespress.io
Last updated: 2026-07-08